Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
J Inorg Biochem ; 260: 112689, 2024 Nov.
Article in English | MEDLINE | ID: mdl-39121601

ABSTRACT

In the search of new cymantrenyl- and ferrocenyl-sulfonamides as potencial inhibitors of human carbonic anhydrases (hCAs), four compounds based on N-ethyl or N-methyl benzenesulfonamide units have been obtained. These cymantrenyl (1a-b) and ferrocenyl (2a-b) derivatives were prepared by the reaction between aminobenzene sulfonamides ([NH2-(CH2)n-(C6H4)-SO2-NH2)], where n = 1, 2) with cymantrenyl sulfonyl chloride (P1) or ferrocenyl sulfonyl chloride (P2), respectively. All compounds were characterized by conventional spectroscopic techniques and cyclic voltammetry. In the solid state, the molecular structures of compounds 1a, 1b, and 2b were determined by single-crystal X-ray diffraction. Biological evaluation as carbonic anhydrases inhibitors were carried out and showed derivatives 1b y 2b present a higher inhibition than the drug control for the Human Carbonic Anhydrase (hCA) II and IX isoforms (KI = 7.3 nM and 5.8 nM, respectively) and behave as selective inhibition for hCA II isoform. Finally, the docking studies confirmed they share the same binding site and interactions as the known inhibitors acetazolamide (AAZ) and agree with biological studies.


Subject(s)
Carbonic Anhydrase Inhibitors , Carbonic Anhydrases , Molecular Docking Simulation , Sulfonamides , Humans , Carbonic Anhydrase Inhibitors/chemistry , Carbonic Anhydrase Inhibitors/chemical synthesis , Carbonic Anhydrase Inhibitors/pharmacology , Sulfonamides/chemistry , Sulfonamides/pharmacology , Sulfonamides/chemical synthesis , Carbonic Anhydrases/metabolism , Carbonic Anhydrases/chemistry , Carbonic Anhydrase II/antagonists & inhibitors , Carbonic Anhydrase II/metabolism , Carbonic Anhydrase II/chemistry , Carbonic Anhydrase IX/antagonists & inhibitors , Carbonic Anhydrase IX/metabolism , Antigens, Neoplasm/metabolism , Antigens, Neoplasm/chemistry , Carbonic Anhydrase I/antagonists & inhibitors , Carbonic Anhydrase I/metabolism , Benzenesulfonamides , Organometallic Compounds/chemistry , Organometallic Compounds/chemical synthesis , Organometallic Compounds/pharmacology , Crystallography, X-Ray
2.
J Mol Cell Cardiol ; 136: 53-63, 2019 11.
Article in English | MEDLINE | ID: mdl-31518570

ABSTRACT

Heart failure is the leading cause of death among diabetic people. Cellular and molecular entities leading to diabetic cardiomyopathy are, however, poorly understood. Coupling of cardiac carbonic anhydrase II (CAII) and Na+/H+ exchanger 1 (NHE1) to form a transport metabolon was analyzed in obese type 2 diabetic mice (ob-/-) and control heterozygous littermates (ob+/-). Echocardiography showed elevated systolic interventricular septum thickness and systolic posterior wall thickness in ob-/- mice at 9 and 16 weeks. ob-/- mice showed increased left ventricular (LV) weight/tibia length ratio and increased cardiomyocyte cross sectional area as compared to controls, indicating cardiac hypertrophy. Immunoblot analysis showed increased CAII expression in LV samples of ob-/-vs. ob+/- mice, and augmented Ser703 phosphorylation on NHE1 in ob-/- hearts. Reciprocal co-immunoprecipitation analysis showed strong association of CAII and NHE1 in LV samples of ob-/- mice. NHE1-dependent rate of intracellular pH (pHi) normalization after transient acid loading of isolated cardiomyocytes was higher in ob-/- mice vs. ob+/-. NHE transport activity was also augmented in cultured H9C2 rat cardiomyoblasts treated with high glucose/high palmitate, and it was normalized after CA inhibition. We conclude that the NHE1/CAII metabolon complex is exacerbated in diabetic cardiomyopathy of ob-/- mice, which may lead to perturbation of pHi and [Na+] and [Ca2+] handling in these diseased hearts.


Subject(s)
Carbonic Anhydrase II/metabolism , Cardiomegaly/pathology , Diabetes Mellitus, Type 2/complications , Sodium-Hydrogen Exchanger 1/metabolism , Animals , Carbonic Anhydrase II/antagonists & inhibitors , Carbonic Anhydrase Inhibitors/pharmacology , Cardiomegaly/diagnostic imaging , Cardiomegaly/metabolism , Diabetes Mellitus, Experimental/complications , Diabetes Mellitus, Experimental/pathology , Diabetes Mellitus, Type 2/metabolism , Diabetes Mellitus, Type 2/pathology , Electrocardiography , Ethoxzolamide/pharmacology , Female , Heart Ventricles/pathology , Hydrogen-Ion Concentration , Mice, Mutant Strains , Mice, Transgenic , Myocytes, Cardiac/metabolism , Myocytes, Cardiac/pathology , Phosphorylation , Protein Processing, Post-Translational , Rats , Serine/metabolism
3.
Bioorg Med Chem Lett ; 26(16): 3892-5, 2016 08 15.
Article in English | MEDLINE | ID: mdl-27423482

ABSTRACT

A small series of N-glycosylsulfonamides incorporating the phenol moiety has been prepared by Ferrier sulfonamidoglycosylation of d-glycals. N-Glycosides were tested for the inhibition of four isoforms of carbonic anhydrase. In this study, all compounds showed good inhibitory activity against hCA I and II, with selectivity against the cytosolic hCA II versus the tumor associated isozymes. These results confirm that attaching carbohydrate moieties to CA phenol pharmacophore improves and enhances its inhibitory activity.


Subject(s)
Carbonic Anhydrase II/metabolism , Carbonic Anhydrase I/metabolism , Carbonic Anhydrase Inhibitors/chemical synthesis , Phenols/chemistry , Sulfonamides/chemistry , Carbonic Anhydrase I/antagonists & inhibitors , Carbonic Anhydrase II/antagonists & inhibitors , Carbonic Anhydrase Inhibitors/chemistry , Carbonic Anhydrase Inhibitors/metabolism , Humans , Neoplasms/metabolism , Neoplasms/pathology , Protein Binding , Protein Isoforms/antagonists & inhibitors , Protein Isoforms/metabolism , Structure-Activity Relationship , Sulfonamides/chemical synthesis , Sulfonamides/metabolism
4.
Biol Res ; 47: 39, 2014 Sep 04.
Article in English | MEDLINE | ID: mdl-25299962

ABSTRACT

BACKGROUND: Novel, in silico-designed anticancer compounds were synthesized in our laboratory namely, 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10),15-tetraen-17-ol (ESE-15-ol) and 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10)16-tetraene (ESE-16). These compounds were designed to have improved bioavailability when compared to their source compound, 2-methoxyestradiol. This theoretically would be due to their increased binding affinity to carbonic anhydrase II, present in erythrocytes. Since the novel compounds under investigation are proposed to be transported within erythrocytes bound to carbonic anhydrase II, the morphological effect which they may exert on whole blood and erythrocytes is of great significance. A secondary outcome included revision of previously reported procedures for the handling of the whole blood sample. The purpose of this study was twofold. Firstly, the ultrastructural morphology of a healthy female's erythrocytes was examined via scanning electron microscopy (SEM) after exposure to the newly in silico-designed compounds. Morphology of erythrocytes following exposure to ESE-15-ol and ESE-16 for 3 minutes and 24 hours at 22°C were described with the use of SEM. The haemolytic activity of the compounds after 24 hours exposure were also determined with the ex vivo haemolysis assay. Secondly, storage conditions of the whole blood sample were investigated by determining morphological changes after a 24 hour storage period at 22°C and 37°C. RESULTS: No significant morphological changes were observed in the erythrocyte morphology after exposure to the novel anticancer compounds. Storage of the whole blood samples at 37°C for 24 hours resulted in visible morphological stress in the erythrocytes. Erythrocytes incubated at 22°C for 24 hours showed no structural deformity or distress. CONCLUSIONS: From this research the optimal temperature for ex vivo exposure of whole blood samples to ESE-15-ol and ESE-16 for 24 hours was determined to be 22°C. Data from this study revealed the potential of these compounds to be applied to ex vivo study techniques, since no damage occurred to erythrocytes ultrastructure under these conditions. As no structural changes were observed in erythrocytes exposed to ESE-15-ol and ESE-16, further ex vivo experiments will be conducted into the potential effects of these compounds on whole blood. Optimal incubation conditions up to 24 hours for whole blood were established as a secondary outcome.


Subject(s)
Antineoplastic Agents/pharmacology , Carbonic Anhydrase Inhibitors/pharmacology , Computer Simulation , Erythrocytes/drug effects , Estradiol/analogs & derivatives , Estrenes/pharmacology , Sulfonamides/pharmacology , Antineoplastic Agents/pharmacokinetics , Biological Availability , Carbonic Anhydrase II/drug effects , Carbonic Anhydrase Inhibitors/pharmacokinetics , Carrier Proteins/pharmacokinetics , Carrier Proteins/pharmacology , Drug Discovery , Erythrocytes/ultrastructure , Estradiol/pharmacokinetics , Estradiol/pharmacology , Estradiol/toxicity , Estrenes/pharmacokinetics , Female , Hemolysis/drug effects , Humans , Microscopy, Electron, Scanning , Middle Aged , Qualitative Research , Sulfonamides/pharmacokinetics , Sulfonamides/toxicity , Temperature
5.
Am J Physiol Cell Physiol ; 307(9): C791-813, 2014 Nov 01.
Article in English | MEDLINE | ID: mdl-24965587

ABSTRACT

The α-carbonic anhydrases (CAs) are zinc-containing enzymes that catalyze the interconversion of CO2 and HCO3 (-). Here, we focus on human CA II (CA II), a ubiquitous cytoplasmic enzyme. In the second paper in this series, we examine CA IV at the extracellular surface. After microinjecting recombinant CA II in a Tris solution (or just Tris) into oocytes, we expose oocytes to 1.5% CO2/10 mM HCO3 (-)/pH 7.50 while using microelectrodes to monitor intracellular pH (pHi) and surface pH (pHS). CO2 influx causes the familiar sustained pHi fall as well as a transient pHS rise; CO2 efflux does the opposite. Both during CO2 addition and removal, CA II increases the magnitudes of the maximal rate of pHi change, (dpHi/dt)max, and the maximal change in pHS, ΔpHS. Preincubating oocytes with the inhibitor ethoxzolamide eliminates the effects of CA II. Compared with pHS, pHi begins to change only after a delay of ~9 s and its relaxation has a larger (i.e., slower) time constant (τpHi > τpHS ). Simultaneous measurements with two pHi electrodes, one superficial and one deep, suggest that impalement depth contributes to pHi delay and higher τpHi . Using higher CO2/HCO3 (-) levels, i.e., 5%/33 mM HCO3 (-) or 10%/66 mM HCO3 (-), increases (dpHi/dt)max and ΔpHS, though not in proportion to the increase in [CO2]. A reaction-diffusion mathematical model (described in the third paper in this series) accounts for the above general features and supports the conclusion that cytosolic CA-consuming entering CO2 or replenishing exiting CO2-increases CO2 fluxes across the cell membrane.


Subject(s)
Carbon Dioxide/metabolism , Carbonic Anhydrase II/metabolism , Cell Membrane/metabolism , Animals , Bicarbonates/metabolism , Biological Transport , Carbonic Anhydrase II/antagonists & inhibitors , Humans , Hydrogen-Ion Concentration , Oocytes/metabolism , Xenopus laevis
6.
J Am Soc Mass Spectrom ; 25(7): 1181-91, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24781457

ABSTRACT

Chemical cross-linking is an attractive low-resolution technique for structural studies of protein complexes. Distance constraints obtained from cross-linked peptides identified by mass spectrometry (MS) are used to construct and validate protein models. Amidinating cross-linkers such as diethyl suberthioimidate (DEST) have been used successfully in chemical cross-linking experiments. In this work, the application of a commercial diimidate cross-linking reagent, dimethyl suberimidate (DMS), was evaluated with model peptides and proteins. The peptides were designed with acetylated N-termini followed by random sequences containing two Lys residues separated by an Arg residue. After cross-linking reactions, intra- and intermolecular cross-linked species were submitted to CID and ECD dissociations to study their fragmentation features in the gas phase. Fragmentation of intramolecular peptides by collision induced dissociation (CID) demonstrates a unique two-step fragmentation pathway involving formation of a ketimine as intermediate. Electron capture and electron transfer dissociation (ECD and ETD) experiments demonstrated that the cyclic moiety is not dissociated. Intermolecular species demonstrated previously described fragmentation behavior in both CID and ECD experiments. The charge state distributions (CSD) obtained after reaction with DMS were compared with those obtained with disuccinimidyl suberate (DSS). CSDs for peptides and proteins were increased after their reaction with DMS, owing to the higher basicity of DMS modified species. These features were also observed in LC-MS experiments with bovine carbonic anhydrase II (BCA) after cross-linking with DMS and tryptic proteolysis. Cross-linked peptides derived from this protein were identified at high confidence and those species were in agreement with the crystal structure of BCA.


Subject(s)
Cross-Linking Reagents/chemistry , Dimethyl Suberimidate/chemistry , Peptides/chemistry , Proteins/chemistry , Proteomics/methods , Animals , Carbonic Anhydrase II/chemistry , Cattle , Models, Molecular
7.
Biol. Res ; 47: 1-7, 2014. ilus, graf
Article in English | LILACS | ID: biblio-950735

ABSTRACT

BACKGROUND: Novel, in silico-designed anticancer compounds were synthesized in our laboratory namely, 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10),15-tetraen-17-ol (ESE-15-ol) and 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10)16-tetraene (ESE-16). These compounds were designed to have improved bioavailability when compared to their source compound, 2-methoxyestradiol. This theoretically would be due to their increased binding affinity to carbonic anhydrase II, present in erythrocytes. Since the novel compounds under investigation are proposed to be transported within erythrocytes bound to carbonic anhydrase II, the morphological effect which they may exert on whole blood and erythrocytes is of great significance. A secondary outcome included revision of previously reported procedures for the handling of the whole blood sample. The purpose of this study was twofold. Firstly, the ultrastructural morphology of a healthy female's erythrocytes was examined via scanning electron microscopy (SEM) after exposure to the newly in silico-designed compounds. Morphology of erythrocytes following exposure to ESE-15-ol and ESE-16 for 3 minutes and 24 hours at 22°C were described with the use of SEM. The haemolytic activity of the compounds after 24 hours exposure were also determined with the ex vivo haemolysis assay. Secondly, storage conditions of the whole blood sample were investigated by determining morphological changes after a 24 hour storage period at 22°C and 37°C. RESULTS: No significant morphological changes were observed in the erythrocyte morphology after exposure to the novel anticancer compounds. Storage of the whole blood samples at 37°C for 24 hours resulted in visible morphological stress in the erythrocytes. Erythrocytes incubated at 22°C for 24 hours showed no structural deformity or distress. CONCLUSIONS: From this research the optimal temperature for ex vivo exposure of whole blood samples to ESE-15-ol and ESE-16 for 24 hours was determined to be 22°C. Data from this study revealed the potential of these compounds to be applied to ex vivo study techniques, since no damage occurred to erythrocytes ultrastructure under these conditions. As no structural changes were observed in erythrocytes exposed to ESE-15-ol and ESE-16, further ex vivo experiments will be conducted into the potential effects of these compounds on whole blood. Optimal incubation conditions up to 24 hours for whole blood were established as a secondary outcome.


Subject(s)
Humans , Female , Middle Aged , Sulfonamides/pharmacology , Computer Simulation , Carbonic Anhydrase Inhibitors/pharmacology , Erythrocytes/drug effects , Estradiol/analogs & derivatives , Estrenes/pharmacology , Antineoplastic Agents/pharmacology , Sulfonamides/toxicity , Sulfonamides/pharmacokinetics , Temperature , Carbonic Anhydrase Inhibitors/pharmacokinetics , Biological Availability , Microscopy, Electron, Scanning , Carrier Proteins/pharmacology , Carrier Proteins/pharmacokinetics , Carbonic Anhydrase II/drug effects , Qualitative Research , Erythrocytes/ultrastructure , Estradiol/toxicity , Estradiol/pharmacology , Estradiol/pharmacokinetics , Estrenes/pharmacokinetics , Drug Discovery , Hemolysis/drug effects , Antineoplastic Agents/pharmacokinetics
8.
Am J Physiol Heart Circ Physiol ; 305(2): H228-37, 2013 Jul 15.
Article in English | MEDLINE | ID: mdl-23709596

ABSTRACT

Myocardial stretch is an established signal that leads to hypertrophy. Myocardial stretch induces a first immediate force increase followed by a slow force response (SFR), which is a consequence of an increased Ca(2+) transient that follows the NHE1 Na(+)/H(+) exchanger activation. Carbonic anhydrase II (CAII) binds to the extreme COOH terminus of NHE1 and regulates its transport activity. We aimed to test the role of CAII bound to NHE1 in the SFR. The SFR and changes in intracellular pH (pHi) were evaluated in rat papillary muscle bathed with CO2/HCO3(-) buffer and stretched from 92% to 98% of the muscle maximal force development length for 10 min in the presence of the CA inhibitor 6-ethoxzolamide (ETZ, 100 µM). SFR control was 120 ± 3% (n = 8) of the rapid initial phase and was fully blocked by ETZ (99 ± 4%, n = 6). The SFR corresponded to a maximal increase in pHi of 0.18 ± 0.02 pH units (n = 4), and pHi changes were blocked by ETZ (0.04 ± 0.04, n = 6), as monitored by epifluorescence. NHE1/CAII physical association was examined in the SFR by coimmunoprecipitation, using muscle lysates. CAII immunoprecipitated with an anti-NHE1 antibody and the CAII immunoprecipitated protein levels increased 58 ± 9% (n = 6) upon stretch of muscles, assessed by immunoblots. The p90(RSK) kinase inhibitor SL0101-1 (10 µM) blocked the SFR of heart muscles after stretch 102 ± 2% (n = 4) and reduced the binding of CAII to NHE1, suggesting that the stretch-induced phosphorylation of NHE1 increases its binding to CAII. CAII/NHE1 interaction constitutes a component of the SFR to heart muscle stretch, which potentiates NHE1-mediated H(+) transport in the myocardium.


Subject(s)
Carbonic Anhydrase II/antagonists & inhibitors , Carbonic Anhydrase Inhibitors/pharmacology , Ethoxzolamide/pharmacology , Muscle Spindles/metabolism , Papillary Muscles/drug effects , Sodium-Hydrogen Exchangers/metabolism , Animals , Carbonic Anhydrase II/metabolism , Extracellular Signal-Regulated MAP Kinases/metabolism , Hydrogen-Ion Concentration , Immunoprecipitation , Luminescent Measurements , Male , Papillary Muscles/enzymology , Phosphorylation , Protein Binding , Protein Interaction Domains and Motifs , Protein Interaction Mapping/methods , Protein Kinase Inhibitors/pharmacology , Rats , Rats, Wistar , Ribosomal Protein S6 Kinases, 90-kDa/antagonists & inhibitors , Ribosomal Protein S6 Kinases, 90-kDa/metabolism , Sodium-Hydrogen Exchanger 1 , Time Factors
9.
Bioorg Med Chem ; 21(6): 1410-8, 2013 Mar 15.
Article in English | MEDLINE | ID: mdl-23266178

ABSTRACT

A set of sulfamides and sulfamates were synthesized and tested against several isoforms of carbonic anhydrase: CA I, CA II, CA VII, CA XII and CA XIV. The biological assays showed a broad range of inhibitory activity, and interesting results were found for several compounds in terms of activity (Ki <1µm) and selectivity: some aromatic sulfamides are active against CA I, CA II and/or CA VII; while they are less active in CA XII and CA XIV. On the other hand, bulky sulfamides are selective to CA VII. To understand the origin of the different inhibitory activity against each isozyme we used molecular modeling techniques such as docking and molecular dynamic simulations.


Subject(s)
Carbonic Anhydrase Inhibitors/chemistry , Carbonic Anhydrases/chemistry , Sulfonamides/chemistry , Binding Sites , Carbonic Anhydrase I/antagonists & inhibitors , Carbonic Anhydrase I/metabolism , Carbonic Anhydrase II/antagonists & inhibitors , Carbonic Anhydrase II/metabolism , Carbonic Anhydrase Inhibitors/chemical synthesis , Carbonic Anhydrase Inhibitors/metabolism , Carbonic Anhydrases/metabolism , Catalytic Domain , Humans , Molecular Docking Simulation , Protein Binding , Sulfonamides/chemical synthesis , Sulfonamides/metabolism
10.
Psicofarmacologia (B. Aires) ; 12(74): 33-36, jun. 2012. tab
Article in Spanish | BINACIS | ID: bin-128992

ABSTRACT

En la presente revisión se analiza cómo el topiramato afecta a corto y largo plazo el estado ácido base mediante la inhibición de la anhidrasa carbónica tipo II, generando una acidosis tubular renal mixta que provoca consecuencias clínicas de importancia como nefrolitiasis, osteoporosis y retraso en el crecimiento. Dado que los tratamientos con este fármaco son crónicos, pueden prevenirse estos sucesos de diversas maneras. Se ofrecen pautas para el manejo de las distintas situaciones clínicas (AU)


This review provides an analysis of the short-and long-term impact of Topiramate on the acid-base status through the inhibition of carbonic anhydrase II, which leads to a mixed renal tubular acidosis that causes significant clinical consequences such as nephrolithiasis, osteoporosis and growth delay. Because treatments with this drug are chronic, these events may be prevented in different ways. The author offers guidelines for the management of different clinical situations (AU)


Subject(s)
Humans , Carbonic Anhydrase II/antagonists & inhibitors , Carbonic Anhydrase Inhibitors , Anticonvulsants/adverse effects
11.
Psicofarmacologia (B. Aires) ; 12(74): 33-36, jun. 2012. tab
Article in Spanish | LILACS | ID: lil-663449

ABSTRACT

En la presente revisión se analiza cómo el topiramato afecta a corto y largo plazo el estado ácido base mediante la inhibición de la anhidrasa carbónica tipo II, generando una acidosis tubular renal mixta que provoca consecuencias clínicas de importancia como nefrolitiasis, osteoporosis y retraso en el crecimiento. Dado que los tratamientos con este fármaco son crónicos, pueden prevenirse estos sucesos de diversas maneras. Se ofrecen pautas para el manejo de las distintas situaciones clínicas


This review provides an analysis of the short-and long-term impact of Topiramate on the acid-base status through the inhibition of carbonic anhydrase II, which leads to a mixed renal tubular acidosis that causes significant clinical consequences such as nephrolithiasis, osteoporosis and growth delay. Because treatments with this drug are chronic, these events may be prevented in different ways. The author offers guidelines for the management of different clinical situations


Subject(s)
Humans , Carbonic Anhydrase II/antagonists & inhibitors , Anticonvulsants/adverse effects , Carbonic Anhydrase Inhibitors
12.
Bioorg Med Chem Lett ; 21(15): 4447-50, 2011 Aug 01.
Article in English | MEDLINE | ID: mdl-21723123

ABSTRACT

The transmembrane isoforms of carbonic anhydrase (CA IX and XII) have been shown to be linked to carcinogenesis and their inhibition to arrest primary tumor and metastases growth. In this Letter, we present a series of peracetylated and deprotected N-ß-glycosyl sulfamides that were tested for the inhibition of 4 carbonic anhydrase isoforms: the cytosolic hCA I and hCA II and transmembrane tumor-associated IX and XII. Compounds 1-4 and 6-8 selectively target cancer-associated CAs (IX and XII) with K(I)s in the low nanomolar range.


Subject(s)
Amides/chemistry , Antigens, Neoplasm/chemistry , Antineoplastic Agents/chemistry , Carbonic Anhydrase Inhibitors/chemistry , Carbonic Anhydrases/chemistry , Amides/chemical synthesis , Amides/pharmacology , Antigens, Neoplasm/metabolism , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/pharmacology , Carbonic Anhydrase I/antagonists & inhibitors , Carbonic Anhydrase I/metabolism , Carbonic Anhydrase II/antagonists & inhibitors , Carbonic Anhydrase II/metabolism , Carbonic Anhydrase IX , Carbonic Anhydrase Inhibitors/chemical synthesis , Carbonic Anhydrase Inhibitors/pharmacology , Carbonic Anhydrases/metabolism , Humans , Neoplasms/enzymology , Structure-Activity Relationship
13.
J Chem Inf Model ; 50(6): 1113-22, 2010 Jun 28.
Article in English | MEDLINE | ID: mdl-20481572

ABSTRACT

Sixteen aromatic and aliphatic sulfamides and sulfamates were synthesized and tested in their inhibition to carbonic anhydrase CAII activity. The weaker inhibition pattern shown by sulfamides as compared to sulfamates is interpreted in this research by means of molecular modeling techniques, including known inhibitors (topiramate and its sulfamide cognate) in the analysis. The results nicely explain the origin of the inhibitory activity, which is not only related to positive interactions of the ligand with the active site residues but also to the solvation pattern characteristic of each ligand.


Subject(s)
Carbonic Anhydrase II/chemistry , Carbonic Anhydrase II/metabolism , Molecular Dynamics Simulation , Sulfonamides/metabolism , Sulfonic Acids/metabolism , Catalytic Domain , Isoenzymes/chemistry , Isoenzymes/metabolism , Ligands , Protein Binding , Solvents/chemistry , Sulfonamides/chemistry , Sulfonic Acids/chemistry , Water/chemistry
14.
FEBS Lett ; 583(21): 3425-30, 2009 Nov 03.
Article in English | MEDLINE | ID: mdl-19808034

ABSTRACT

Gamma carbonic anhydrases (gammaCA) are widespread in Prokaryotes. In Eukaryotes, homologous genes were found only in plant genomes. In Arabidopsis and maize, the corresponding gene products are subunits of mitochondrial Complex I. At present, only gammaCA homotrimers of Methanosarcina thermophila (CAM) show reversible carbon dioxide (CO(2)) hydration activity. In the present work, it is shown that recombinant plant gammaCA2 could form homotrimers and bind H(14)CO(3)(-). However, they are unable to catalyse the reversible hydration of CO(2). These results suggest that plant gammaCAs do not act as carbonic anhydrases but with a related activity possibly contributing to recycle CO(2) in the context of photorespiration.


Subject(s)
Arabidopsis/enzymology , Carbon/metabolism , Carbonic Anhydrase II/chemistry , Carbonic Anhydrase II/metabolism , Protein Multimerization , Protein Structure, Quaternary , Amino Acid Sequence , Bicarbonates/metabolism , Carbon Radioisotopes , Carbonic Acid/metabolism , Carbonic Anhydrase II/genetics , Carbonic Anhydrase II/isolation & purification , Molecular Sequence Data , Protein Binding , Protein Subunits/chemistry , Protein Subunits/genetics , Protein Subunits/isolation & purification , Protein Subunits/metabolism , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/isolation & purification , Recombinant Proteins/metabolism , Solubility , Water/metabolism
16.
Platelets ; 16(7): 392-7, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16236600

ABSTRACT

Recently, our laboratory has reported the presence of one acidifying Cl-/HC exchange mechanism in human platelets. This paper demonstrates that this exchanger decreases its activity after inhibition of carbonic anhydrase. BCECF-loaded platelets, previously equilibrated in a bicarbonate/CO2 buffered solution, were resuspended in a Hepes-buffered, chloride-free (glucuronate) medium to produce a pHi increase. After addition of 50 mM NaCl, pHi fell rapidly reaching steady state in the succeeding 400 s. The recovery in chloride-containing solution was in contrast to the effect of a similar change in osmolarity by addition of 50 mM sodium glucuronate that produced a significantly slower variation of pHi. Alkali loads produced by 25 mM TMA were also counteracted by HC equivalent efflux via Cl-/HC exchange. The present study shows that the efflux of HC was slower when the platelets were previously incubated in 100 microM methazolamide. As a conclusion, the recovery of pHi from alkalosis by Na-independent Cl-/HC exchange is facilitated in platelets by the enzymatic activity of the carbonic anhydrase.


Subject(s)
Bicarbonates/metabolism , Blood Platelets/metabolism , Carbonic Anhydrases/metabolism , Chloride-Bicarbonate Antiporters/metabolism , Chlorides/metabolism , Isoenzymes/metabolism , Buffers , Carbonic Anhydrase II/metabolism , Carbonic Anhydrase Inhibitors/metabolism , Fluorescent Dyes/metabolism , HEPES/metabolism , Humans , Hydrogen-Ion Concentration , Methazolamide/metabolism
17.
Am J Reprod Immunol ; 53(2): 85-93, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15790342

ABSTRACT

PROBLEM: In view of evidences suggesting association between endometriosis (EM) and systemic lupus erythematosus (SLE), we have performed a comparative evaluation of clinical and humoral immunologic abnormalities in both diseases. METHOD OF STUDY: Forty-five women (18-40 years) with histologically confirmed pelvic EM, 21 healthy-women and 15 female SLE-patients (18-40 years) without surgically confirmed EM were prospectively evaluated. Immunologic investigations were performed by blinded researchers. RESULTS: None of the EM-patients fulfilled criteria for SLE. However, EM-patients presented higher frequencies of arthralgia (62%) and generalized myalgia (18%) superior than normal-controls (24%, P = 0.004/0%, P = 0.048) but comparable with SLE-patients (33%, P = 0.052/27%, P = 0.5). Similarly to SLE (7%), 9% of EM-patients presented fibromyalgia. Antinuclear antibodies (ANA) were detected in 18% of EM-sera, as compared with healthy-women (0%, P = 0.014) and SLE-patients (93%, P = 0.0005). In contrast with SLE, antibodies to dsDNA, Sm and U1RNP were negative in EM-sera. Anti-Ro and anticardiolipin antibodies were more often in SLE (40%, 33%) than in EM-patients (2%, P < 0.001/9%, P = 0.04). Elevated immune-complexes and low total complement were more frequent in SLE (40%, 13%) compared with EM-sera (7%, P = 0.005/0%, P = 0.01). CONCLUSIONS: Our data indicate differences of ANA antigenic specificity and complement consumption between EM and SLE. The high prevalence of generalized musculoskeletal complaints in EM justifies a multidisciplinary approach.


Subject(s)
Endometriosis/immunology , Lupus Erythematosus, Systemic/immunology , Adolescent , Adult , Antibodies, Anticardiolipin/blood , Antibodies, Antinuclear/blood , Arthritis/blood , Arthritis/immunology , Carbonic Anhydrase II/immunology , Complement System Proteins/immunology , Demography , Double-Blind Method , Endometriosis/diagnosis , Epitopes/immunology , Female , Fibromyalgia/blood , Fibromyalgia/immunology , Humans , Lupus Erythematosus, Systemic/diagnosis , Prospective Studies , Rheumatoid Factor/blood , Serologic Tests
SELECTION OF CITATIONS
SEARCH DETAIL